Within this work, we aimed not only at the investigation of the HDAC class I novel inhibitor hydrazostat’s anticancer effectiveness in leukemia and neuroblastoma cell models, but also at the identification of the additional vulnerabilities of cancer cells tightly linked with HDACs. This evidence concerns the gene HDAC9 and cancer.